The fears are based on mechanism and animal data, not observed human cancer cases simply because BPC-157 hasnt been studied in humans long enough or in enough people to see those outcomes
Now you know if you've been here for a while that we really rely on you as the listener, the subscriber and the podcast
Neelakantan and colleagues (Biochem Pharmacol, 2017) then took the pharmacological step, reporting that selective, membrane-permeable small-molecule NNMT inhibitors reversed high-fat-diet-induced obesity in mice this is the study most directly relevant to the 5-Amino-1MQ class, because it moves from the target matters to a drug against the target does something in a live animal. And again, it is a mouse study
biology and engineering must both weigh in
But not all peptides are as well researchedwhich is one of the primary reasons why the FDA recently released new regulations limiting the sale of certain prescription peptide treatments
We may consider these comments for future rulemaking, guidance, resources, and as part of our HPT monitoring process
